Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7148
Browse
3 results
Search Results
Now showing 1 - 3 of 3
Article Citation - WoS: 2Citation - Scopus: 6Immobilization of Olive Leaf Extract With Chitosan Nanoparticles as an Adjunct To Enhance Cytotoxicity(American Chemical Society, 2023) Özdamar, Burcu; Sürmeli, Yusuf; Şanlı Mohamed, GülşahWe immobilized the olive leaf extract (OLE) with chitosannanoparticles(CNPs) by optimizing the effect of various immobilization conditions,and OLE-loaded CNPs (OLE-CNPs) were then elaborately characterizedphysicochemically by scanning electron microscopy (SEM), Fourier transforminfrared (FT-IR) spectroscopy, dynamic light scattering (DLS), andatomic force microscopy (AFM). Under optimal conditions, CNPs wereable to accommodate the OLE with a loading capacity of 97.5%. Theresulting OLE-CNPs had a spherical morphology, and their average diameterwas approximately 100 nm. The cytotoxic influence, cell cycle distribution,and apoptosis stage of OLE and OLE-CNPs were analyzed on lung carcinoma(A549) and breast adenocarcinoma (MCF-7) cell lines. In an in vitrocytotoxic assay, IC50 values of OLE-CNPs were determinedto be 540 & mu;g/mL for A549 and 810 & mu;g/mL for MCF-7. Thetreatment of both A549 and MCF-7 with OLE-CNPs caused the highestcell arrest in G0/G1 in a dose-independent manner. OLE-CNPs affectedcell cycle distribution in a manner different from free OLE treatmentin both cancer cells. A549 and MCF-7 cells were predominantly foundin the late apoptosis and necrosis phases, respectively, upon treatmentof 1000 & mu;M OLE-CNPs. Our results suggest that CNPs enhance theutility of OLEs as nutraceuticals in cancer and that OLE-CNPs canbe utilized as an adjunct to cancer therapy.Review Citation - WoS: 96Citation - Scopus: 112Therapeutic Potential of Luteolin on Cancer(MDPI, 2023) Çetinkaya, Melisa; Baran, YusufCancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids-natural compounds produced by plants as secondary metabolites for cancer therapy-has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types.Book Part Citation - Scopus: 6Recent Advances in Chitosan-Based Systems for Delivery of Anticancer Drugs(Springer, 2020) Polat, Mehmet; Polat, HürriyetProblems in transporting drug molecules to tumor sites in required dose or constitution lead to low efficacy and significant side effects. Shielding the drug molecules in micelles, liposomes, or nanoparticles is a major line of investigation to improve chemotherapeutic treatment. Though compatibility for proper envelopment of the drug and timely release at the tumor site are required of such a carrier, protecting its own physicochemical and morphological integrity during transport is another precondition. Because of its superior polymerization capability, biocompatibility, pH dependence, and charging characteristics, chitosan has been in the forefront of potential drug carriers. Numerous synthesis routes for chitosan-based nanocarriers have been suggested to the extent that a search of the literature published since 2000 with the keywords “novel + nano + chitosan” in the title results in 527 articles, indicating the bewildering quality and quantity of the new information. This review was carried out not only to peruse this large amount of work on chitosan-based anticancer drug delivery but also to extract manageable patterns from numerous synthesis routes. The main conclusion is that the synthesis methods suggested in literature can be combined into two main routes, and the degree of hydrophobicity of the drug determines which route should be followed. © Springer Nature Singapore Pte Ltd. 2019.